RiboX Therapeutics

Focus: RiboX Therapeutics is a circular RNA-focused biotech company headquartered in Shanghai developing gene therapy candidates for autoimmune and regenerative medicine indications. The company operates at an early-stage, pre-revenue research phase with a focused pipeline.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About RiboX Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow RiboX Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RXIM002 product

Relapsed/Refractory B Cell-Mediated Autoimmune Diseases

Phase 1

Clinical Trials (1)

NCT07322718Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases

Phase 1

Help build intelligence for RiboX Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build expertise in circular RNA—an emerging modality with significant intellectual property upside and differentiation from mRNA competitors
Early-stage company structure enables meaningful impact on drug development strategy and scientific direction before organizational scaling
Gene therapy focus addresses high-unmet-need indications with potential for premium valuations and partnership interest from larger players

Watch Out For

No active job openings currently listed, indicating potential hiring freeze or limited near-term growth capacity
Pre-clinical/Phase 1 pipeline with no revenue and undisclosed funding create significant uncertainty around runway, cash position, and long-term viability

Generated by Claude from RiboX Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RXRG001

Radiation-Induced Xerostomia and Hyposalivation

Phase 1/2

Clinical Trials (1)

NCT06714253Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Immunology

1 pipeline

Marketed

Pipeline